Buemi M, Allegra A, Laganà A, Aloisi C, Privitera M, Morabito N, Frisina N
Institute of Internal Medicine, 1th University of Messina, Italy.
Riv Eur Sci Med Farmacol. 1993 Sep-Dec;15(5-6):195-7.
The authors evaluated the possibility that the time of the administration of erythropoietin (rHuEPO) may play any effect on the therapeutic outcome of the treatment. The study was carried out on 26 uremic subjects submitted to hemodialysis in the morning or in the evening. At the end of the dialytic treatment every patient was administered rHuEPO IV. The amount of erythropoietin needed to reach an Ht value of 32% was evaluated. The subjects whose rHuEPO had been administered in the first evening hours showed that they needed a less quantity of rHuEPO (885 +/- 50 vs 1550 +/- 75 IU/Kg; p < 0.01), and showed a more rapid improvement of the anemia. According to the lans of a physiologic circadian rhythm, the evening i.v. administration of rHuEPO seems to insure a quicker therapeutic success.
作者评估了促红细胞生成素（rHuEPO）给药时间可能对治疗效果产生任何影响的可能性。该研究针对26名在上午或晚上进行血液透析的尿毒症患者开展。在透析治疗结束时，给每位患者静脉注射rHuEPO。评估达到血细胞比容（Ht）值32%所需的促红细胞生成素量。在傍晚较早时间接受rHuEPO治疗的受试者显示，他们所需的rHuEPO量较少（885±50 vs 1550±75 IU/Kg；p<0.01），并且贫血改善更快。根据生理昼夜节律，傍晚静脉注射rHuEPO似乎能确保更快的治疗成功。
